
Our pick · Oct 2026
Embody
from $49/mo
Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
- LegitScript certified
Our pick is a commercial choice. We may earn a commission when you join.
Does Alabama Medicaid cover GLP-1s for weight loss?
If you are an adult and weight loss is your only reason, Alabama Medicaid does not cover a GLP-1.
If one of the uses below applies to you, your prescriber can ask Alabama Medicaid to cover that drug. Read the rule and its criteria.
Which drugs Alabama Medicaid covers, and for what:
We checked 2 official documents on October 15, 2026. This is information, not medical advice or a benefit decision.
5 programs that serve Alabama publish a complete monthly price, from $49 at Embody to $297 at Direct Meds GLP-1.

Our pick · Oct 2026
from $49/mo
Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
Our pick is a commercial choice. We may earn a commission when you join.
Some programs are affiliate partners, and we may earn a commission if you join through our link. Payment never moves a row. How we rank

Compounded semaglutide · 12-mo prepay
$588 up front
Advertised program price, not an insurance copay.
Good: 7.6/10 · Compounded
Checked Oct 16, 2026; a rating claim didn't match Trustpilot.
$588 upfront for 12 months of semaglutide. Yearly-plan sale ends December 1; confirm renewal. Paid terms are normally non-refundable; provider-determined medical disqualification allows a refund for the unused term, less services already provided.
The October 27–December 1, 2026 sale offers semaglutide at $49/month equivalent ($588 prepaid for twelve months) and tirzepatide at $99/month equivalent ($1,188 prepaid). One-month plans remain $79 and $129. The published terms say the rate stays fixed on the selected plan. Confirm the renewal amount and date before paying; these sale rates are not month-to-month bills.
We checked this price on Oct 27, 2026.
Full review and sources
12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Fair: 7.3/10 · Compounded
Checked Jul 18, 2026; few independent reviews yet.
$1,188 paid once for the 12-month semaglutide plan; does not renew. Separate monthly subscription: $99 first, then $165. Confirm how four-week vial supplies cover the billing term.
12-month semaglutide one-time plan: $1,188 paid up front, with no renewal. Separate monthly Subscribe and Save is $99 for the first month, then $165. Product pages describe four-week vials; confirm supply coverage across the selected billing term.
We checked this price on Sep 3, 2026.
Full review and sources
Compounded semaglutide lozenge · auto-refill
Advertised program price, not an insurance copay.
Fair: 6.5/10 · Compounded
Checked Oct 16, 2026.
as low as, auto-refill
We checked this price on Oct 2, 2026.
Full review and sources$99/mo equivalent at Trimi Health
12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Good: 7.6/10 · Compounded
Checked Jul 2, 2026.
$1,188 upfront for 12 months; applicable taxes may add to the bill 12-month prepay: $1,188 upfront ($99 monthly equivalent); does not auto-renew. The separate month-to-month semaglutide plan is $175
We checked this price on Oct 20, 2026.
Full review and sourcesfrom$297/mo at Direct Meds GLP-1

Confirm the full bill
Advertised program price, not an insurance copay.
Good: 7.5/10 · Compounded
Checked Oct 16, 2026.
Confirm the current prescribed treatment and full bill with the provider.
We checked this price on Sep 3, 2026.
Full review and sources1 more program serves Alabama without one complete monthly price: Wellorithm. Compare their terms in the price index.
We left out 27 programs whose service-area list has a caveat for Alabama or is incomplete, so confirm your address at intake.
A program that serves Alabama still decides whether to prescribe. Before enrolling, confirm whether it accepts your Medicaid plan and whether your prescribed treatment is covered. The advertised cash prices are not insurance copays. Most listed programs sell compounded semaglutide or tirzepatide, which is not FDA-approved. Check a compounded provider before you pay.
Here is our summary of the Alabama Medicaid rules we checked, with their criteria and limits.
Alabama Medicaid covers Wegovy only if you have heart disease or MASH and Zepbound only if you have sleep apnea, not either drug for weight loss alone, under its preferred drug list and prior authorization instructions effective October 1, 2026. Your prescriber can request Wegovy if you are an adult with established heart disease and a BMI of 27 or more, or if you have MASH, a fatty liver disease, with stage F2 or F3 scarring. Alabama Medicaid prefers Zepbound, with criteria, if you are an adult with moderate to severe obstructive sleep apnea and a BMI of 30 or more. For the sleep apnea and MASH routes, you cannot have a diabetes diagnosis, and to renew, your prescriber sends recent weight records or, for sleep apnea, proof that your sleep improved. The FDA has approved only the Wegovy injection for MASH. Alabama Medicaid does not list Saxenda or Foundayo. Before you pay cash, ask your prescriber to match your diagnosis and product to the current criteria; Alabama Medicaid still decides each request. We did not confirm every exception for children.
A drug on the preferred list is not covered for every use, so check the rule for yours. A weight-loss exclusion leaves diabetes and other medical requests to their own rules.
We checked Alabama Medicaid PDL Reference Tool, effective October 1, 2026 (incretin mimetics, page 14) on October 15, 2026.
We checked Alabama Medicaid PA criteria instructions, effective October 1, 2026 (non-diabetes incretin mimetics, page 22) on October 15, 2026.
Alabama Medicaid also lists Xenical (orlistat capsules), an oral medicine that is not a GLP-1, in its prior authorization instructions effective October 1, 2026. It appears in the separate non-preferred drug list section: that means prior authorization is required, not that coverage is automatically excluded. Xenical has its own rules, separate from the GLP-1 indications above.
The criteria include age, BMI and associated-diagnosis requirements, documentation of unsuccessful physician-supervised diet and exercise treatment, and height and weight records. Renewals require weight records showing continued loss. A listed pathway does not guarantee approval or establish coverage for every weight-loss pill, generic orlistat or over-the-counter Alli. Ask your prescriber to check your exact prescribed product and circumstances against the current Xenical criteria.
We checked Alabama Medicaid PA criteria instructions, effective October 1, 2026 (Xenical, pages 3, 68 and 79) on November 4, 2026.
We checked FDA prescribing information for Xenical (orlistat) capsules, revised September 2026 on November 4, 2026.
Call your Medicaid plan, Medicare drug plan or private insurer with these questions, and keep the reference number for each call.
Before you pay cash, confirm:
An “insurance accepted” badge does not tell you your benefit, so ask your plan how its review works.
Your prescriber sends Alabama Medicaid a request with the records that show you meet the rule for your drug and diagnosis, and Alabama Medicaid decides.
What Alabama Medicaid's own criteria ask for, from the documents we read:
What your prescriber usually sends:
Your prescriber works from these Alabama Medicaid documents:
Your prescriber's office files the request; you cannot file it yourself. If Alabama Medicaid says no, ask for the reason in writing, because the notice tells you how to ask for a review and by when.
Medicare's GLP-1 Bridge follows federal rules in every state, so Alabama Medicaid's policy does not decide your Medicare benefit.
We checked CMS's Bridge guidance for Part D plans on September 26, 2026.
Two free official services can help you, and we earn no commission from either.
Alabama Medicaid covers Wegovy only if you have heart disease or MASH and Zepbound only if you have sleep apnea, not either drug for weight loss alone, under its preferred drug list and prior authorization instructions effective October 1, 2026.
Your prescriber can request Wegovy if you are an adult with established heart disease and a BMI of 27 or more, or if you have MASH, a fatty liver disease, with stage F2 or F3 scarring. Alabama Medicaid prefers Zepbound, with criteria, if you are an adult with moderate to severe obstructive sleep apnea and a BMI of 30 or more. For the sleep apnea and MASH routes, you cannot have a diabetes diagnosis, and to renew, your prescriber sends recent weight records or, for sleep apnea, proof that your sleep improved. The FDA has approved only the Wegovy injection for MASH. Alabama Medicaid does not list Saxenda or Foundayo. Before you pay cash, ask your prescriber to match your diagnosis and product to the current criteria; Alabama Medicaid still decides each request. We did not confirm every exception for children. Before you pay, confirm your exact drug, your diagnosis, any age rules and your plan's authorization steps.
Yes.
Medicare's GLP-1 Bridge follows federal eligibility rules in every state, not Alabama Medicaid's policy. Your ordinary Part D coverage depends on your prescription and your drug plan, and the Bridge runs its own eligibility and authorization review.
Yes, from 6 online programs that publish a service area including Alabama.
At intake, confirm your address, the exact medication and any pharmacy limits, because a state listing does not guarantee you a prescription or a delivery date.
Among programs that serve Alabama, the lowest complete monthly price we found is $49 at Embody.
Across the 9 compounded programs we track nationally, the median advertised recurring price is $99/mo, from $49 to $299. That national figure is not a measured Alabama average, insurance copay or quote for your dose.
Affiliate partners we feature. We may earn a commission.
Check the medication, commitment and total price for your selected plan.
Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. Published scores have different evidence limits and do not establish better care. See the program comparison and scoring limitations.